Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience, Inc. (NASDAQ:DARE) announced that results from its postcoital test (PCT) clinical study of Ovaprene, a hormone-free monthly intravaginal contraceptive, will be presented at the 2021 ACOG Annual Meeting from April 30 to May 2, 2021. The topline results indicate Ovaprene effectively prevented motile sperm from entering the cervical canal. Medical Director, Christine Mauck, expressed confidence in advancing to a pivotal effectiveness study pending FDA approval. The virtual presentation will be accessible on the ACOG website starting April 30, 2021.
Daré Bioscience, Inc. (NASDAQ:DARE) announced positive topline results from its Phase 3 DARE-BVFREE study of DARE-BV1, a vaginal gel for treating bacterial vaginosis, set to be presented at the ACOG Annual Meeting from April 30 to May 2, 2021. The study involved 307 women, showing a clinical cure rate of 70% for the DARE-BV1 group compared to 36% for the placebo at Day 21-30. Notably, DARE-BV1 outperformed existing treatments in terms of efficacy and was well-tolerated with no adverse event-related discontinuations.
Daré Bioscience (NASDAQ: DARE) announced the appointment of Dr. Sophia N. Ononye-Onyia to its Board of Directors. Dr. Ononye-Onyia brings extensive experience in women's health commercialization, having held senior roles in global biopharmaceutical companies. Her leadership is expected to guide Daré's product candidates, including DARE-BV1, towards successful market entry. Dr. Ononye-Onyia is the founder of The Sophia Consulting Firm and has a strong background in medicinal chemistry and public health. This strategic appointment aims to enhance shareholder value.
Daré Bioscience (NASDAQ: DARE) reported its financial results for the year ending December 31, 2020. The company achieved a commercial partnership with Bayer for Ovaprene, potentially bringing in up to $310 million in milestone payments. The completion of its first Phase 3 study for DARE-BV1 showed a 76% clinical cure rate for bacterial vaginosis. Financially, the company reported a comprehensive loss of $27.4 million, with significant increases in R&D expenses. Cash equivalents were $4.7 million, with $29.5 million in net cash received during FY2020. Future objectives include NDA submissions and ongoing clinical trials.
Daré Bioscience Initiates Phase 2b RESPOND Study
On March 24, 2021, Daré Bioscience (NASDAQ:DARE) announced the start of the Phase 2b RESPOND clinical study for Sildenafil Cream, 3.6%, targeting female sexual arousal disorder (FSAD). This topical formulation of sildenafil aims to directly enhance blood flow to the genital area, potentially becoming the first FDA-approved treatment for FSAD. The study will involve approximately 400 to 590 subjects and aims for topline data by year-end 2021. FSAD affects around 10 million U.S. women, highlighting a significant market opportunity.
Daré Bioscience (NASDAQ: DARE) announced a conference call on March 30, 2021, at 4:30 p.m. ET to discuss its year-end financial results for 2020 and provide company updates. Interested participants can access the call via phone or live webcast on the company's investor relations website. Daré focuses on women's health, developing innovative products including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1, aimed at enhancing treatment options in contraception and women’s health.
Daré Bioscience (NASDAQ: DARE) announced the completion of patient recruitment for its Phase 1 clinical trial of DARE-HRT1, an intravaginal ring designed to deliver bio-identical hormones for menopause treatment. The trial aims to assess pharmacokinetics and safety in approximately 30 post-menopausal women. Topline data is expected in Q2 2021. This study could position DARE-HRT1 as a first-in-category product, offering a novel option for hormone therapy. The company plans to utilize existing safety data for regulatory approval through the FDA’s 505(b)(2) pathway.
Daré Bioscience announced that CEO Sabrina Martucci Johnson will participate in two virtual conferences: the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17-18, 2021, with presentations available on-demand, and BIO-Europe Spring Digital from March 22-25, 2021. Following the M Vest conference, a webcast will be accessible for two weeks via the company's investor relations website.
Daré focuses on innovative women's health products, including unique therapies for contraception and sexual health.
Daré Bioscience, Inc. (NASDAQ: DARE) announces that President and CEO Sabrina Martucci Johnson will participate in a panel on 'Women’s Health Companies Blazing the Trail' at the 33rd Annual Roth Conference from March 15-17, 2021. The panel discussion will highlight innovations in women's health. A webcast will be available on March 15, 2021, at 5:00 PM ET on their website, remaining accessible until March 29, 2021. Daré focuses on developing therapies for contraception, vaginal health, sexual health, and fertility.
Daré Bioscience, a leader in women's health innovation, will have its CEO, Sabrina Martucci Johnson, present at the H.C. Wainwright Global Life Sciences Conference from March 9 to 10, 2021. The presentation will be accessible starting March 9, 2021, at 7:00 AM EST on the company's website. Daré Bioscience focuses on developing innovative therapies for women's health, including products for contraception, sexual health, and hormone replacement therapy. Key candidates in their pipeline include Ovaprene and Sildenafil Cream for female sexual arousal disorder.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
